Gefitinib: new preparation. Non small-cell lung cancer: stricter assessment needed.

Abstract

(1) Platinum-based chemotherapy is generally used to treat advanced-stage non small-cell lung cancer (stages III and IV), but has only a modest impact on survival. There is no reference treatment. (2) Gefitinib inhibits the tyrosine kinase activity of the receptor for EGF (epidermal growth factor), which is thought to be involved in tumour growth. It has a temporary licence in France and is used on a named-patient basis, but full marketing authorisation has already been granted in Japan, the United States, and elsewhere. (3) Two double-blind dose-finding studies compared two doses of oral gefitinib monotherapy (250 mg/day and 500 mg/day) in patients in whom at least two lines of chemotherapy had failed. The results were favourable, with a median survival of 6 months and a symptomatic improvement in some patients, but they are undermined by the absence of a placebo group and by major protocol violations. (4) Two double-blind trials, each in more than 1000 patients, showed that gefitinib does not increase the efficacy of first-line platinum combinations. (5) About 15% of patients receiving gefitinib monotherapy in clinical trials stopped taking the treatment because of adverse events. The most frequent were gastrointestinal (diarrhea, nausea, vomiting) and cutaneous (rash, acne, dry skin, pruritus). (6) Interstitial pneumonitis occurred in about 1% of patients, and was fatal in about one-third of cases. (7) Gefitinib is metabolised by the cytochrome P450 isoenzyme CYP3A4, so carries a potentially high risk of interactions. (8) In practice, more thorough assessment of gefitinib is needed to determine whether this new drug is beneficial for patients with non small-cell lung cancer. Marketing authorisation is not currently justified.

• Journal: Prescrire international (Prescrire Int) Vol. 13 Issue 73 Pg. 168-70 (Oct 2004) ISSN: 1167-7422 [Print] France
• PMID: 15499696 (Publication Type: Journal Article)

Chemical References

• Antineoplastic Agents
• Quinazolines

Topics

• Antineoplastic Agents (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Drug Approval
• France
• Japan
• Lung Neoplasms (drug therapy)
• Quinazolines (administration & dosage, adverse effects, pharmacokinetics, therapeutic use)
• Randomized Controlled Trials as Topic
• Survival Analysis
• Treatment Outcome
• United States